{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T17:15:56Z","timestamp":1793466956619,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"am","delay-in-days":378,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007188","name":"Uniformed Services University of the Health Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["fertstertscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["F&S Science"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.xfss.2024.12.004","type":"journal-article","created":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:51:39Z","timestamp":1735347099000},"page":"213-220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Relugolix reduces leiomyoma extracellular matrix production via the transforming growth factor-beta pathway"],"prefix":"10.1016","volume":"6","author":[{"given":"Adina","family":"Schwartz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minnie","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Driggers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Catherino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xfss.2024.12.004_bib1","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1067\/mob.2003.99","article-title":"High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence","volume":"188","author":"Baird","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.xfss.2024.12.004_bib2","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1097\/01.AOG.0000285997.38553.4b","article-title":"Hysterectomy rates in the United States, 2003","volume":"110","author":"Wu","year":"2007","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.xfss.2024.12.004_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ogc.2005.12.004","article-title":"Epidemiology of myomas","volume":"33","author":"Payson","year":"2006","journal-title":"Obstet Gynecol Clin North Am"},{"key":"10.1016\/j.xfss.2024.12.004_bib4","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1111\/1471-0528.14640","article-title":"Epidemiology of uterine fibroids: a systematic review","volume":"124","author":"Stewart","year":"2017","journal-title":"BJOG"},{"key":"10.1016\/j.xfss.2024.12.004_bib5","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/AOG.0b013e318299a6cf","article-title":"Nationwide trends in the performance of inpatient hysterectomy in the United States","volume":"122","author":"Wright","year":"2013","journal-title":"Obstet Gynecol"},{"issue":"Suppl 3","key":"10.1016\/j.xfss.2024.12.004_bib6","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.fertnstert.2004.04.030","article-title":"Comparative ultrastructure of collagen fibrils in uterine leiomyomas and normal myometrium","volume":"82","author":"Leppert","year":"2004","journal-title":"Fertil Steril"},{"key":"10.1016\/j.xfss.2024.12.004_bib7","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/783289","article-title":"The extracellular matrix contributes to mechanotransduction in uterine fibroids","volume":"2014","author":"Leppert","year":"2014","journal-title":"Obstet Gynecol Int"},{"key":"10.1016\/j.xfss.2024.12.004_bib8","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/humupd\/dmx032","article-title":"Extracellular matrix in uterine leiomyoma pathogenesis: a potential target for future therapeutics","volume":"24","author":"Islam","year":"2018","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.xfss.2024.12.004_bib9","first-page":"69","article-title":"Transforming growth factor-beta: a key mediator of fibrosis","volume":"117","author":"Mauviel","year":"2005","journal-title":"Methods Mol Med"},{"key":"10.1016\/j.xfss.2024.12.004_bib10","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1046\/j.1523-1747.2002.01641.x","article-title":"Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation","volume":"118","author":"Verrecchia","year":"2002","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.xfss.2024.12.004_bib11","doi-asserted-by":"crossref","first-page":"L525","DOI":"10.1152\/ajplung.00163.2007","article-title":"TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease","volume":"293","author":"Willis","year":"2007","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.xfss.2024.12.004_bib12","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1053\/jhep.2002.32673","article-title":"Dose-dependent inhibition of hepatic fibrosis in mice by a TGF-beta soluble receptor: implications for antifibrotic therapy","volume":"35","author":"Yata","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.xfss.2024.12.004_bib13","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/sj.ki.5000054","article-title":"Renal fibrosis: new insights into the pathogenesis and therapeutics","volume":"69","author":"Liu","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.xfss.2024.12.004_bib14","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.autrev.2006.06.001","article-title":"Transforming growth factor-beta signaling through the Smad proteins: role in systemic sclerosis","volume":"5","author":"Verrecchia","year":"2006","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.xfss.2024.12.004_bib15","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.4049\/jimmunol.175.8.5390","article-title":"TGF-beta and Smad3 signaling link inflammation to chronic fibrogenesis","volume":"175","author":"Bonniaud","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.xfss.2024.12.004_bib16","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/S0015-0282(00)00418-0","article-title":"Transforming growth factor-beta3 is expressed at high levels in leiomyoma where it stimulates fibronectin expression and cell proliferation","volume":"73","author":"Arici","year":"2000","journal-title":"Fertil Steril"},{"key":"10.1016\/j.xfss.2024.12.004_bib17","first-page":"913","article-title":"Human leiomyoma smooth muscle cells show increased expression of transforming growth factor-beta 3 (TGF beta 3) and altered responses to the antiproliferative effects of TGF beta","volume":"86","author":"Lee","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.xfss.2024.12.004_bib18","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1055\/s-2004-828614","article-title":"Gene expression studies in leiomyomata: new directions for research","volume":"22","author":"Catherino","year":"2004","journal-title":"Semin Reprod Med"},{"key":"10.1016\/j.xfss.2024.12.004_bib19","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.fertnstert.2009.01.081","article-title":"Myometrial cells undergo fibrotic transformation under the influence of transforming growth factor beta-3","volume":"93","author":"Joseph","year":"2010","journal-title":"Fertil Steril"},{"key":"10.1016\/j.xfss.2024.12.004_bib20","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1097\/AOG.0000000000004401","article-title":"ACOG practice bulletin, number 228","volume":"137","year":"2021","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.xfss.2024.12.004_bib21","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/GRF.0000000000000171","article-title":"An evidence-based approach to the medical management of fibroids: a systematic review","volume":"59","author":"Bartels","year":"2016","journal-title":"Clin Obstet Gynecol"},{"key":"10.1016\/j.xfss.2024.12.004_bib22","first-page":"CD000154","article-title":"Combined hormonal contraceptives for heavy menstrual bleeding","volume":"2","author":"Lethaby","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.xfss.2024.12.004_bib23","first-page":"CD008994","article-title":"Progestogens or progestogen-releasing intrauterine systems for uterine fibroids","volume":"2","author":"Sangkomkamhang","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.xfss.2024.12.004_bib24","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/AOG.0b013e3181f20177","article-title":"Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial","volume":"116","author":"Lukes","year":"2010","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.xfss.2024.12.004_bib27","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJMoa2008283","article-title":"Treatment of uterine fibroid symptoms with relugolix combination therapy","volume":"384","author":"Al-Hendy","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xfss.2024.12.004_bib28","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/2414609","article-title":"A comprehensive review of the pharmacologic management of uterine leiomyoma","volume":"2018","author":"Lewis","year":"2018","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.xfss.2024.12.004_bib29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.fertnstert.2006.11.098","article-title":"Human myometrium and leiomyomas express gonadotropin-releasing hormone 2 and gonadotropin-releasing hormone 2 receptor","volume":"88","author":"Parker","year":"2007","journal-title":"Fertil Steril"},{"key":"10.1016\/j.xfss.2024.12.004_bib30","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.fertnstert.2012.07.1123","article-title":"Gonadotropin-releasing hormone (GnRH) agonist leuprolide acetate and GnRH antagonist cetrorelix acetate directly inhibit leiomyoma extracellular matrix production","volume":"98","author":"Britten","year":"2012","journal-title":"Fertil Steril"},{"key":"10.1016\/j.xfss.2024.12.004_bib31","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.fertnstert.2015.09.006","article-title":"Gonadotropin-releasing hormone analogues inhibit leiomyoma extracellular matrix despite presence of gonadal hormones","volume":"105","author":"Malik","year":"2016","journal-title":"Fertil Steril"},{"key":"10.1016\/j.xfss.2024.12.004_bib32","first-page":"299","article-title":"Relugolix and elagolix directly inhibit leiomyoma extracellular matrix production in 2-dimesnional and 3-dimensional cell cultures","volume":"3","author":"Wright","year":"2022","journal-title":"F S Sci"},{"key":"10.1016\/j.xfss.2024.12.004_bib33","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.fertnstert.2006.08.111","article-title":"Novel method to characterize primary cultures of leiomyoma and myometrium with the use of confirmatory biomarker gene arrays","volume":"87","author":"Malik","year":"2007","journal-title":"Fertil Steril"},{"key":"10.1016\/j.xfss.2024.12.004_bib34","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1365-2265.2008.03207.x","article-title":"Retinoic acid treatment of human leiomyoma cells transformed the cell phenotype to one strongly resembling myometrial cells","volume":"69","author":"Malik","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.xfss.2024.12.004_bib35","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.fertnstert.2018.07.024","article-title":"Simvastatin, at clinically relevant concentrations, affects human uterine leiomyoma growth and extracellular matrix production","volume":"110","author":"Malik","year":"2018","journal-title":"Fertil Steril"},{"key":"10.1016\/j.xfss.2024.12.004_bib36","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/AOG.0000000000003141","article-title":"Oral gonadotropin-releasing hormone antagonist relugolix compared with leuprorelin injections for uterine leiomyomas: a randomized controlled trial","volume":"133","author":"Osuga","year":"2019","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.xfss.2024.12.004_bib37","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1177\/1933719109343310","article-title":"Transforming growth factor beta3 regulates the versican variants in the extracellular matrix-rich uterine leiomyomas","volume":"16","author":"Norian","year":"2009","journal-title":"Reprod Sci"},{"key":"10.1016\/j.xfss.2024.12.004_bib38","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.fertnstert.2018.12.026","article-title":"Ulipristal acetate decreases active TGF-\u03b23 and its canonical signaling in uterine leiomyoma via two novel mechanisms","volume":"111","author":"Lewis","year":"2019","journal-title":"Fertil Steril"},{"key":"10.1016\/j.xfss.2024.12.004_bib39","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/0006-2952(94)90137-6","article-title":"Liarozole fumarate inhibits the metabolism of 4-keto-all-trans-retinoic acid","volume":"47","author":"Van Wauwe","year":"1994","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.xfss.2024.12.004_bib40","first-page":"89","article-title":"Liarozole potentiates the all-trans-retinoic acid-induced structural remodelling in human breast carcinoma MCF-7 cells in vitro","volume":"71","author":"Van Heusden","year":"1996","journal-title":"Eur J Cell Biol"},{"key":"10.1016\/j.xfss.2024.12.004_bib41","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.fertnstert.2012.07.1132","article-title":"Leiomyoma fibrosis inhibited by liarozole, a retinoic acid metabolic blocking agent","volume":"98","author":"Gilden","year":"2012","journal-title":"Fertil Steril"},{"key":"10.1016\/j.xfss.2024.12.004_bib42","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.fertnstert.2014.03.042","article-title":"Liarozole inhibits transforming growth factor-\u03b23--mediated extracellular matrix formation in human three-dimensional leiomyoma cultures","volume":"102","author":"Levy","year":"2014","journal-title":"Fertil Steril"},{"key":"10.1016\/j.xfss.2024.12.004_bib43","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1097\/AOG.0b013e3181705d0e","article-title":"CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial","volume":"111","author":"Levens","year":"2008","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.xfss.2024.12.004_bib44","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.fertnstert.2010.09.059","article-title":"Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study","volume":"95","author":"Nieman","year":"2011","journal-title":"Fertil Steril"},{"key":"10.1016\/j.xfss.2024.12.004_bib45","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.fertnstert.2014.02.008","article-title":"Long-term treatment of uterine fibroids with ulipristal acetate","volume":"101","author":"Donnez","year":"2014","journal-title":"Fertil Steril"},{"key":"10.1016\/j.xfss.2024.12.004_bib46","doi-asserted-by":"crossref","first-page":"17053","DOI":"10.1073\/pnas.1313650110","article-title":"Paracrine activation of WNT\/\u03b2-catenin pathway in uterine leiomyoma stem cells promotes tumor growth","volume":"110","author":"Ono","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.xfss.2024.12.004_bib47","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1007\/s11010-021-04174-6","article-title":"Wnt\/\u03b2-catenin signaling pathway in uterine leiomyoma: role in tumor biology and targeting opportunities","volume":"476","author":"El","year":"2021","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.xfss.2024.12.004_bib48","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1095\/biolreprod.108.075648","article-title":"Constitutive activation of beta-catenin in uterine stroma and smooth muscle leads to the development of mesenchymal tumors in mice","volume":"81","author":"Tanwar","year":"2009","journal-title":"Biol Reprod"},{"key":"10.1016\/j.xfss.2024.12.004_bib49","doi-asserted-by":"crossref","first-page":"L956","DOI":"10.1152\/ajplung.00123.2011","article-title":"\u03b2-catenin signaling is required for TGF-\u03b21-induced extracellular matrix production by airway smooth muscle cells","volume":"301","author":"Baarsma","year":"2011","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.xfss.2024.12.004_bib50","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/nrd1902","article-title":"Exploiting the PI3K\/AKT pathway for cancer drug discovery","volume":"4","author":"Hennessy","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.xfss.2024.12.004_bib51","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1101\/gad.13.22.2905","article-title":"Cellular survival: a play in three Akts","volume":"13","author":"Datta","year":"1999","journal-title":"Genes Dev"},{"key":"10.1016\/j.xfss.2024.12.004_bib52","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jsbmb.2003.09.007","article-title":"Differential expression of Akt\/protein kinase B, Bcl-2 and Bax proteins in human leiomyoma and myometrium","volume":"87","author":"Kov\u00e1cs","year":"2003","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.xfss.2024.12.004_bib53","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1210\/jc.2008-2093","article-title":"Progestins activate the AKT pathway in leiomyoma cells and promote survival","volume":"94","author":"Hoekstra","year":"2009","journal-title":"J Clin Endocrinol Metab"}],"container-title":["F&S Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666335X24000843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666335X24000843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T05:29:01Z","timestamp":1747286941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666335X24000843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2666335X24000843"],"URL":"https:\/\/doi.org\/10.1016\/j.xfss.2024.12.004","relation":{},"ISSN":["2666-335X"],"issn-type":[{"value":"2666-335X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relugolix reduces leiomyoma extracellular matrix production via the transforming growth factor-beta pathway","name":"articletitle","label":"Article Title"},{"value":"F&S Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xfss.2024.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of American Society for Reproductive Medicine.","name":"copyright","label":"Copyright"}]}}